Study Summary
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).
Want to learn more about this trial?
Request More InfoInterventions
SC-DARIC33BIOLOGICAL
Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Seattle Children's Hospital | Seattle | Washington | United States |